医疗补助扩展与PSA筛查推荐对抗:政策博弈对筛查率的影响
基于2012-2018年BRFSS数据,分析医疗补助扩展与USPSTF反对PSA筛查推荐对筛查率的相对影响。早期扩展州<138%联邦贫困线男性2011-2013年筛查率增加7.3%,但未持续;2014年计划扩展州2015-2017年变化-0.4%,而早期扩展州和非扩展州分别下降6.7%和8.6%。结论认为USPSTF推荐常压倒医疗可及性改善的影响。
要点
- 早期扩展州<138%贫困线男性2011-2013年PSA筛查率增加7.3%,但未持续。
- 2014年计划扩展州2015-2017年筛查变化-0.4%,小于早期扩展州(-6.7%)和非扩展州(-8.6%)。
- USPSTF反对筛查推荐对PSA筛查率的影响常超过医疗补助扩展带来的可及性改善。
核心结论
- 医疗补助扩展与USPSTF反对PSA筛查推荐竞争,后者常占上风。
- 早期扩展州<138%贫困线男性初始筛查增加不持久,最终跟随全国下降趋势。
- 计划扩展州<138%贫困线男性2016-2018年全球下降被可及性扩展所抵消。
研究设计与样本
- 分析2012-2018年行为危险因素监测系统(BRFSS)数据,评估自我报告的PSA筛查和保险覆盖趋势。
- 亚组分析包括州医疗补助扩展状态和受访者联邦贫困水平。
- 采用多变量逻辑回归评估与PSA筛查相关的因素。
主要发现
- 2012-2018年PSA筛查总体下降,例外为早期扩展州<138%联邦贫困线男性2011-2013年增加7.3%。
- 2014年计划扩展州2015-2017年变化-0.4%,早期扩展州和非扩展州分别下降6.7%和8.6%。
- 早期扩展州<138%贫困线男性初始增加未持续,2018年筛查趋势与非扩展州相似。
临床怎么用
- 临床医生应知晓USPSTF推荐对PSA筛查行为的强影响,在共享决策中平衡政策与个体化评估。
- 对于医疗补助扩展州低收入男性,需关注筛查可及性改善但筛查率仍可能受指南推荐制约。
局限性
- 研究为观察性分析,无法确立因果关系。
- 依赖自我报告的PSA筛查数据,可能存在回忆偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Medicaid expansion under the Patient Protection and Affordable Care Act occurred almost concurrently with 2012 U.S. Preventive Services Task Force recommendations against prostate specific antigen screening. Here the relative influence on prostate specific antigen screening rates by 2 concurrent and opposing system-level policy initiatives is investigated: improved access to care and change in clinical practice guidelines. MATERIALS AND METHODS: Behavioral Risk Factor Surveillance System data from years 2012 to 2018 were analyzed for trends in self-reported prostate specific antigen screening and insurance coverage. Subanalyses included state Medicaid expansion status and respondent federal poverty level. Multivariable logistic regression was performed to evaluate factors associated with prostate specific antigen screening. RESULTS: From 2012 to 2018 prostate specific antigen screening predominantly declined with a notable exception of an increase of 7.3% for men at <138% federal poverty level between 2011 and 2013 in early expansion states. Initial increases did not continue, and screening trends mirrored those of nonexpansion states by 2018. Notably, 2014 planned expansions states did not follow this trend with minimal change between 2015 and 2017 compared to declines in early expansion states and nonexpansion states (-0.4% vs -6.7% and -8.6%, respectively). CONCLUSIONS: Medicaid expansion was associated with increased rates of insured men at <138% federal poverty level from 2012 to 2018 in early expansion states. In this group, initial increases in prostate specific antigen screening were not durable and followed the trend of reduced screening seen across the United States. In planned expansions states the global drop in prostate specific antigen screening from 2016 to 2018 was offset in men at <138% federal poverty level by expanding access to care. Nonexpansion states showed a steady decline in prostate specific antigen screening rates. This suggests that policy such as U.S. Preventive Services Task Force recommendations against screening competes with and often outmatches access to care.
引用
- Daly WC, Linscott JA, Han PKJ, et al. National Recommendations against Prostate Specific Antigen Screening versus Statewide Medicaid Expansion Initiatives: A Battle of the Titans. J Urol. 2021. PMID: 33530748. doi:10.1097/JU.0000000000001594
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。